Exergaming for Residual Dizziness and Balance in BPPV
NCT07922421, Not applicable, Completed, Afyonkarahisar Health Sciences University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Exergaming for Residual Dizziness and Balance in BPPV | ClinicalTrials.gov |
| NCT number | NCT07922421 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 51 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Afyonkarahisar Health Sciences University | ClinicalTrials.gov |
| Conditions | Benign Paroxysmal Positional Vertigo (BPPV) | ClinicalTrials.gov |
| Interventions | Vestibular Rehabilitation, exergaming, control group | ClinicalTrials.gov |
| First posted | 2026-11-06 | ClinicalTrials.gov |
| Last updated | 2026-11-06 | ClinicalTrials.gov |
Registered outcomes 3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | balance | before treatment and 6 weeks later | With Kinvent Plates, patients' static balance was tested while standing on two feet with their eyes open, while standing on two feet with their eyes closed, and their dynamic balance was tested by jumping from a platform. | ClinicalTrials.gov |
| Secondary | Dizziness Disability Inventory | before treatment and 6 weeks later | The inventory consists of 25 items that determine the sensory and functional outcomes in vestibular system disorders, as well as factors that aggravate dizziness and balance disorders in patients. The sub-inventories aim to determine the physical, sensory, and functional effects of vestibular system disorders. Each question consists of yes (4 points), no (0 points), and sometimes (2) answers. In scoring the sub-units of the inventory, 28 points is suggested as a threshold for determining physical disability, and 36 points for determining functional and sensory disability. High scores are interpreted as indicating that the patient's dizziness significantly impairs their daily life. | ClinicalTrials.gov |
| Secondary | Vertigo Symptom Scale | before treatment and 6 weeks later | The Vertigo Symptom Scale (VSS) is used to assess the frequency of symptoms commonly encountered in patients with vertigo and imbalance, including imbalance, somatic symptoms, autonomic symptoms, anxiety, and panic. The scale consists of two sub-sections: the Vertigo Symptom Scale-Vertigo Section, related to vertigo and balance disorders, and the Vertigo Symptom Scale-Anxiety Section, related to autonomic disorders and anxiety symptoms. It comprises a total of 15 questions. • VSS-V consists of 8 questions (0-32 points), * VSS-A consists of 7 questions (0-28 points). • The frequency of symptoms is scored on a scale of 0 = never, 1 = very rarely, 2 = often, 3 = frequently (every week), and 4 = very frequently (more than 1 day a week on average). * Patients are asked to answer these questions regarding their dizziness based on their experiences over the past month. * High scores (maximum 60) indicate an increased frequency of experiencing vertigo-related symptoms in patients. • A scor | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)